ストックスクリーナーアプリを入手
32.29
0.40%
0.13
プレマーケット:
32.29
前日終値:
$32.16
開ける：
$32.115
24時間の取引高:
2.81M
Relative Volume:
0.78
時価総額：
$5.26B
収益：
$56.99M
当期純損益:
$-107.23M
株価収益率:
-39.38
EPS:
-0.8199
ネットキャッシュフロー:
$-142.55M
1週間 パフォーマンス:
+12.59%
1か月 パフォーマンス:
+57.05%
6か月 パフォーマンス:
+267.77%
1年 パフォーマンス:
+572.01%
1日の値動き範囲:
$31.52
$34.39
1週間の範囲:
$28.07
$34.39
52週間の値動き範囲:
$4.60
$34.39
Tango Therapeutics Inc Stock (TNGX) Company Profile
Compare TNGX vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TNGX
Tango Therapeutics Inc
|
32.29 | 5.36B | 56.99M | -107.23M | -142.55M | -0.8199 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-02 | 開始されました | Canaccord Genuity | Buy |
| 2026-02-23 | 開始されました | Mizuho | Outperform |
| 2025-11-18 | 開始されました | Wolfe Research | Peer Perform |
| 2025-08-19 | 開始されました | Piper Sandler | Overweight |
| 2024-07-17 | 開始されました | Jefferies | Buy |
| 2024-04-04 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-02-12 | 開始されました | Piper Sandler | Overweight |
| 2023-12-08 | 開始されました | B. Riley Securities | Buy |
| 2022-10-20 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2021-09-20 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Tango Therapeutics Inc (TNGX) 最新ニュース
Why is Tango Therapeutics stock surging today? By Investing.com - Investing.com Nigeria
symbol__ Stock Quote Price and Forecast - CNN
H.C. Wainwright Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $66 - Moomoo
Tango Therapeutics prices upsized $600M public offering at $30/share - MSN
CCORF Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $42 - Moomoo
[144] Tango Therapeutics, Inc. SEC Filing - Stock Titan
Tango Therapeutics Announces Major Underwritten Equity Offering - TipRanks
Tango Therapeutics Prices $600 Million Stock Offering - Moomoo
A Quick Look at Today's Ratings for Tango Therapeutics(TNGX.US), With a Forecast Between $32 to $66 - Moomoo
Tango Therapeutics Prices $566.5 Million Equity Offering at $30 Per Share; 30-Day Option Granted - TradingView
Tango Therapeutics (NASDAQ: TNGX) prices $566.5M stock and warrant offering - Stock Titan
Tango Therapeutics (TNGX) raises ~$566.5M via 18.17M shares and pre-funded warrants - Stock Titan
Insider sale notice — TNGX (NASDAQ:TNGX) reports planned share sales - Stock Titan
Tango Therapeutics stock price target raised to $66 by H.C. Wainwright on trial data - Investing.com
Tango Therapeutics stock hits all-time high at 32.69 USD By Investing.com - Investing.com India
Is Tango Therapeutics (TNGX) Price Justified After Its 7x Surge In One Year - Yahoo Finance
Tango Therapeutics prices $600M upsized public offering - scanx.trade
Tango Therapeutics prices $600 million stock offering - Investing.com India
Tango Therapeutics prices $600 million stock offering By Investing.com - Investing.com India
Tango Therapeutics Announces Pricing of $600 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - Quiver Quantitative
Tango Therapeutics Announces Pricing of $600 Million Upsized Public Offering - The Manila Times
Tango Therapeutics Offering Prefunded Warrants to Purchase Up to 1.8M Shares at $29.999 Each >TNGX - Moomoo
Tango Therapeutics Inc (TNGX) News, Articles, Events & Latest Updates - Stocktwits
H.C. Wainwright Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Raises Target Price to $66 - Moomoo
Tango Therapeutics launches $500 million stock offering By Investing.com - Investing.com Australia
Tango Therapeutics: Combo Data With Revolution's RAS Inhibitor Whets Risk Appetite (TNGX) - Seeking Alpha
Tango Therapeutics stock rockets 53% on pancreatic cancer data - grafa.com
TNGX Maintained by HC Wainwright & Co. -- Price Target Raised to $66 - GuruFocus
Tango Therapeutics stock hits all-time high at 32.69 USD - Investing.com
TNGX Stock Jumps 53% on Early Pancreatic Cancer Study Results - Yahoo Finance
TNGX Maintained by Canaccord Genuity -- Price Target Raised to $42 - GuruFocus
Tango Therapeutics stock surges on pancreatic cancer trial data - qz.com
Tango Therapeutics Is Maintained at Buy by Canaccord Genuity - Moomoo
Tango Therapeutics (TNGX) Stock Soars on Pancreatic Cancer Trial Results - Barchart.com
Canaccord raises Tango Therapeutics stock price target on drug combo By Investing.com - Investing.com Nigeria
Canaccord raises Tango Therapeutics stock price target on drug combo - Investing.com
B. Riley Raises Price Target on Tango Therapeutics to $35 From $21, Keeps Buy Rating - marketscreener.com
Tango Therapeutics Stock Soars 53% After Pancreatic Cancer Trial Stuns Wall Street - TIKR.com
Tango Therapeutics Shares Surge 53% on Promising Pancreatic Cancer Trial Data - International Business Times Australia
Why Tango Therapeutics (TNGX) Is Up 33.9% After Highlighting Pancreatic Cancer Pipeline Data Prospects - simplywall.st
Top Biotech Gainers: TNGX Hits New High, ALVO Moves Closer To FDA Approval, ZVRA, IDYA Turn Heads - RTTNews
Apple, SUNation Energy, Tango Therapeutics, Applied Digital And Cerebras Systems: Why These 5 Stocks Are - Benzinga
Tango Therapeutics stock soars on promising pancreatic cancer data - CryptoRank
TNGX stock hits all-time high – Wolfe Research calls Tango Therapeutic’s pancreatic cancer trial data ‘groundbreaking’ - MSN
Tango’s PRMT5 inhibitor adds to daraxonrasib activity in pancreatic cancer - BioCentury
Tango Therapeutics, Inc. Stock 12‑Month Price Target Raised to $36.91, Implies 83% Upside - TradingView
Tango Therapeutics (TNGX) director receives 4,000 RSUs and 25,000-share option grant - Stock Titan
Tango Therapeutics Inc (TNGX) 財務データ
収益
当期純利益
現金流量
EPS
2.60%
0.94%
大文字化:
|
ボリューム (24 時間):